May 2013

The latest from Cogstate, leaders in optimizing the measurement of cognition

Big name boards are a boon for biotech

May 7, 2013

A number of small Australian biotechnology companies are beginning to turn a profit. Shares in Australian company Cogstate (ASX: CGS) have hovered under 40¢ for the past six months despite the company’s revenue rising 48 per cent to $12 million in 2012 and a net profit after tax of $2.5 million. It is conducting its first public trials […]

Education, health services appeal

May 1, 2013

AFR Small Caps writer, Jake Mitchell reported on the education and health testing services industry, featuring CogState’s computerised cognition test as one of the examples of the industry which caters to a large market opportunity in dementia and other psychological conditions. CogState’s deal with Merck Canada has also been referenced. Mitchell states, “CogState sells its […]